Cellular Immune Profiling after Sequential Clofarabine and Lenalidomide for High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML.
Source: Leukemia Research Reports - Category: Hematology Source Type: research